Welcome to our dedicated page for Ideaya Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences stock.
IDEAYA Biosciences Inc. (IDYA) is a clinical-stage biotechnology leader advancing precision oncology therapies through synthetic lethality and biomarker-driven approaches. This news hub provides investors and researchers with timely updates on IDYA's innovative pipeline, strategic collaborations, and scientific advancements in targeting cancer vulnerabilities.
Access authoritative reporting on clinical trial progress, regulatory milestones, and research breakthroughs. Our curated collection includes press releases detailing IDEAYA's novel small molecule therapies, molecular diagnostic developments, and partnerships advancing personalized cancer treatments.
Key updates cover therapeutic candidates targeting DNA damage response pathways, tumor microenvironment innovations, and biomarker validation studies. Stay informed about IDEAYA's pioneering work in matched oncology therapies through verified financial filings and scientific disclosures.
Bookmark this page for consolidated access to essential IDYA developments, carefully sourced to support informed analysis of the company's position in the precision medicine landscape. Check regularly for new updates on clinical data readouts and strategic initiatives shaping the future of targeted cancer treatment.
IDEAYA Biosciences has initiated a Phase 1 clinical trial evaluating IDE161, a selective PARG inhibitor, in patients with homologous recombination deficiency (HRD) solid tumors, particularly focusing on ER+ / Her2- breast cancer.
This trial, marked by the dosing of the first patient, aims to assess the drug's safety, tolerability, and preliminary efficacy as a monotherapy. IDE161 holds potential as a treatment for approximately 10% to 14% of breast cancer patients with HRD, who currently have limited treatment options.
Presented at AACR 2023, this research outlines IDE161's promise and the company's plans for expansion into various HRD tumor cohorts, emphasizing its strategic focus on precision medicine in oncology.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced its participation in investor relations events, including a fireside chat at Cantor's The Future of Oncology Virtual Symposium on April 4, 2023, at 2:15 PM ET. The discussion features CEO Yujiro Hata and is hosted by Li Watsek. Interested parties can access a live audio webcast through the IDEAYA website. The company focuses on precision medicine and synthetic lethality, aiming to develop targeted therapeutics using molecular diagnostics. IDEAYA emphasizes the importance of identifying patient populations most likely to benefit from its therapies.
On March 30, 2023, IDEAYA Biosciences (NASDAQ: IDYA) granted stock options for 79,700 shares to two newly hired employees under the 2023 Employment Inducement Incentive Award Plan. This action complies with Nasdaq Listing Rule 5635(c)(4), which allows the use of this plan for non-former employees. The stock options have an exercise price of $13.49 per share, equal to the closing price on the grant date, and feature a 10-year term with four-year vesting. This development reinforces IDEAYA's commitment to its workforce as it advances its targeted therapeutics in precision medicine oncology.
IDEAYA Biosciences (NASDAQ: IDYA) announced the publication of abstracts for its synthetic lethality programs at the 2023 AACR Annual Meeting. The company will present data on IDE397, a MAT2A inhibitor, and IDE161, a PARG inhibitor, both in Phase 1/2 trials, along with a preclinical Werner Helicase program. Notable presentations include dual inhibition of MAT2A and PRMT5, and targeting HRD breast and ovarian tumors. IDEAYA is collaborating with Amgen and GSK for these programs. The company aims for further clinical developments and eligibility for up to $10 million in milestone payments in connection with its Werner Helicase program.
IDEAYA Biosciences reported a strong cash position of approximately $373.1 million as of December 31, 2022, sufficient to fund operations into 2026. The company is advancing its lead program, darovasertib, targeting ocular melanoma, with regulatory updates anticipated after a Q1 2023 FDA meeting. Clinical updates for darovasertib are expected mid-year 2023, aiming for an overall response rate >20% and a median progression-free survival >5 months. IDEAYA also plans IND submissions for IDE161 and Pol Theta Helicase candidates in 2023, alongside collaborations with GSK and Amgen to expand its pipeline.
IDEAYA Biosciences (NASDAQ: IDYA) announced its participation in two key investor conferences in March 2023. The first is the Oppenheimer 33rd Annual Healthcare Conference on March 14, where CSO Michael White and CMO Darrin Beaupre will engage in a fireside chat. The second is the Guggenheim 4th Annual Healthy Altitudes Summit on March 15, featuring CEO Yujiro S. Hata. Live audio webcasts will be available on IDEAYA's website, with replays accessible for 30 days post-event. The company is committed to developing targeted therapeutics using molecular diagnostics, focusing on synthetic lethality in oncology.
IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, will participate in Citi's 2023 Virtual Oncology Leadership Summit on February 21, 2023, at 9:00 AM ET. The event features a fireside chat with President and CEO Yujiro S. Hata, hosted by Dr. Yigal D. Nochomovitz. Investors can access a live audio webcast via IDEAYA's website, with a replay available for 30 days after the event.
IDEAYA focuses on synthetic lethality and targeted therapeutics, using molecular diagnostics to identify patient populations that benefit from its innovative therapies. The company is dedicated to advancing precision medicine in oncology.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) announced its participation in the 2023 Guggenheim Oncology Conference, scheduled for February 9, 2023, at 7:45 AM PT. The event will feature a fireside chat with President and CEO Yujiro S. Hata and Chief Scientific Officer Michael White, hosted by equity research analyst Charles Zhu, Ph.D. A live audio webcast of the discussion will be available on IDEAYA's website, with a replay accessible for 30 days post-event. IDEAYA focuses on synthetic lethality and precision medicine, developing targeted therapeutics based on molecular diagnostics to enhance treatment efficacy for selected patient populations.
IDEAYA Biosciences has initiated a Phase 2 clinical trial to evaluate darovasertib as a neoadjuvant treatment for uveal melanoma (UM) before primary therapies like enucleation or radiation. The study focuses on eye preservation, reduced radiation, and functional vision. With an annual incidence of about 8,700 cases in the US and EU, UM presents a significant unmet medical need. The trial protocol allows for darovasertib treatment for up to six months, followed by primary treatment and adjuvant therapy. Clinical data updates, particularly on darovasertib combined with crizotinib for metastatic UM, are anticipated in 2023.
IDEAYA Biosciences announced FDA clearance for its IND application, enabling the Phase 1 clinical trial of IDE161, a novel PARG inhibitor for tumors with homologous recombination deficiencies (HRD), particularly in breast and ovarian cancer patients with BRCA mutations. Dosing is set to commence in Q1 2023, starting at half the estimated efficacious dose from preclinical studies. The trial focuses on ER+/Her2- breast cancer, constituting 10-14% of cases. IDEAYA will present IDE161's profile at the J.P. Morgan Healthcare Conference on January 10, 2023.
